Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Shares Outstanding (Diluted Average) (2019 - 2026)

Collegium Pharmaceutical has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $40.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 0.86% year-over-year to $40.1 million; the TTM value through Dec 2025 reached $40.1 million, down 0.86%, while the annual FY2025 figure was $40.1 million, 0.86% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $40.1 million at Collegium Pharmaceutical, up from $39.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $41.8 million in Q4 2023 and troughed at $32.8 million in Q1 2025.
  • A 3-year average of $39.5 million and a median of $40.2 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • On a YoY basis, Shares Outstanding (Diluted Average) climbed as much as 0.86% in 2025 and fell as far as 20.75% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $41.8 million in 2023, then dropped by 3.26% to $40.4 million in 2024, then decreased by 0.86% to $40.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for COLL at $40.1 million in Q4 2025, $39.4 million in Q3 2025, and $39.1 million in Q2 2025.